![]() |
市場調查報告書
商品編碼
1497580
再生醫學中的人工智慧市場:按技術、產品、應用和最終用戶分類 - 2024-2030 年全球預測Artificial Intelligence in Regenerative Medicine Market by Technology (Computer Vision, Context-Aware Computing, Machine Learning), Offering (Hardware, Services, Software), Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年人工智慧再生醫學市場規模為5,963萬美元,預計2024年將達7,238萬美元,2030年將達到2.4063億美元,複合年成長率為22.05%。
人工智慧 (AI) 在再生醫學中變得越來越重要,因為它是一種修復、替換和再生人體內受損或失去的組織和器官的多學科方法。人工智慧技術正在應用於再生醫學的各個方面,以加速研究、增強患者治療並改善治療結果。再生醫學市場中的人工智慧包括將機器學習演算法、深度學習系統、自然語言處理工具和機器人等人工智慧技術整合到幹細胞療法、組織工程、免疫療法和基因編輯技術中。公共和私營部門對研發活動的資金增加正在加速人工智慧等先進技術的採用。此外,癌症和心血管疾病等慢性疾病的盛行率不斷上升,需要創新的治療方法,而這些方法只能透過人工智慧驅動的再生醫學提供的突破性解決方案來解決,需求不斷增加,市場成長進一步加快。然而,用於訓練人工智慧演算法的患者資訊的敏感性引發了資料隱私問題,而人工智慧系統使用的複雜演算法阻礙了市場的採用。個人化治療的出現和次世代定序(NGS)技術的進步正在產生大量需要先進分析技術的資料,為人工智慧在再生醫學中的應用創造了新的機會。
主要市場統計 | |
---|---|
基準年[2023] | 5963萬美元 |
預測年份 [2024] | 7238萬美元 |
預測年份 [2030] | 24063萬美元 |
複合年成長率(%) | 22.05% |
區域洞察
由於擁有大量投資、合作夥伴關係以及持續關注市場創新的主要市場參與者,美洲在再生醫學人工智慧市場中佔據關鍵地位。此外,政府的主導正在匯集各領域的研究人員,專注於整合人工智慧技術,開發器官再生和修復的新治療方法。在歐盟 (EU),地平線 2020 等資助計畫正在分配大量資源來推進以人工智慧為基礎的再生醫學計劃。政府推出了幾個計劃,使用機器學習演算法來繪製人類的每種細胞類型,進一步刺激了該地區的市場採用。在政府大量投資的支持下,亞太地區正在快速推動以人工智慧為基礎的再生醫學。主要公司正在建立專門的醫療保健部門,將人工智慧技術應用於醫療問題,包括再生療法。政府也啟動了戰略舉措,開發再生醫學人工智慧技術,以支持醫療保健和生物技術等產業,進一步加速該地區的市場採用。
FPNV定位矩陣
FPNV 定位矩陣對於評估再生醫學市場人工智慧供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對再生醫學市場人工智慧供應商的現狀進行深入而詳細的評估。對供應商貢獻的徹底比較和分析可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對再生醫學市場人工智慧當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[185 Pages Report] The Artificial Intelligence in Regenerative Medicine Market size was estimated at USD 59.63 million in 2023 and expected to reach USD 72.38 million in 2024, at a CAGR 22.05% to reach USD 240.63 million by 2030.
Artificial intelligence (AI) is increasingly important in regenerative medicine as it is a multidisciplinary approach to repairing, replacing, or regenerating damaged or lost tissues and organs within the human body. AI technologies are applied to various aspects of regenerative medicine to accelerate research, enhance patient care, and improve treatment outcomes. The AI in the regenerative medicine market encompasses integrating AI technologies such as machine learning algorithms, deep learning systems, natural language processing tools, and robotics with stem cell therapy, tissue engineering, immunotherapies, and gene editing techniques. Increased funding for research & development activities in both public and private sectors has accelerated the adoption of advanced technologies such as AI. Additionally, the rising prevalence of chronic conditions such as cancer and cardiovascular diseases has increased demand for innovative treatment approaches that can only be met through groundbreaking solutions provided by AI-enabled regenerative medicine, further increasing market growth. However, data privacy concerns arise due to the sensitive nature of patient information used for training AI algorithms, and the complex algorithms used by AI systems hamper market adoption. The advent of personalized therapy and advances in next-generation sequencing (NGS) technologies have generated vast amounts of data requiring sophisticated analysis methods; this poses yet another opportunity for AI's application within the regenerative medicine landscape.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 59.63 million |
Estimated Year [2024] | USD 72.38 million |
Forecast Year [2030] | USD 240.63 million |
CAGR (%) | 22.05% |
Regional Insights
The Americas hold a significant landscape in the artificial intelligence in regenerative medicine market owing to significant investments and partnerships and the presence of key market players continuously focusing on innovations in the market. Additionally, the government initiative brings together researchers from various fields who focus on integrating AI technologies to develop novel therapeutic approaches for organ regeneration and repair. In the European Union, funding programs such as Horizon 2020 have allocated substantial resources to advance AI-based regenerative medicine projects. The government has launched several projects to map every human cell type using machine learning algorithms, further fueling the region's market adoption. APAC region is rapidly advancing in AI-based regenerative medicine, backed by significant government investments. Leading companies have established dedicated healthcare units that apply AI technologies to medical issues, including regenerative therapies. The government has also launched strategic initiatives to develop AI technologies for regenerative medicine to support industries such as healthcare and biotechnology, further fueling market adoption in the region.
Market Insights
The market dynamics represent an ever-changing landscape of the Artificial Intelligence in Regenerative Medicine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Artificial Intelligence in Regenerative Medicine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Artificial Intelligence in Regenerative Medicine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Axolotl Biologix and Carmell Therapeutics Enter Merger Deal
Axolotl and Carmell entered into a merger agreement to advance Artificial Intelligence (AI) in Regenerative Medicine. This merger will create a company with the largest AI platform for optimizing human tissue development. Both companies will share their AI, data science, and 3D organ fabrication expertise. Through this collaboration, they aim to facilitate innovation in cellular therapies and drug development, strongly focusing on improving patient outcomes. [Published On: 2023-09-13]
Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine Partnership Will Pave the Way for New RegenMed Clinical Trials Catalyst Program
PHC Group announced to expand its presence in regenerative medicine by joining the RegeneratOR Innovation Accelerator. The combination of diagnostic microscopic imaging and AI has created a bridge between drug discovery, translational, and clinical research programs, enabling a better understanding of disease states. [Published On: 2023-01-19]
Wipro and Pandorum Partner to Accelerate Regenerative Medicine with Artificial Intelligence
Wipro entered into a strategic partnership with Pandorum Technologies, aiming to expedite advancements in regenerative medicine through AI. This collaboration between the two companies involves the development of therapies and diagnostics, leveraging predictive analytics and multi-modal data integration. By combining Pandorum's expertise in tissue engineering technology with Wipro's extensive experience in building AI-driven medical solutions, the partnership seeks to accelerate the progress of innovative regenerative therapies. [Published On: 2022-03-11]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Artificial Intelligence in Regenerative Medicine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Artificial Intelligence in Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include Cognetivity Ltd., F. Hoffmann-La Roche Ltd., Intel Corporation, Medtronic PLC, Merck KGaA, Microsoft Corporation, NANO-X IMAGING LTD., Novo Nordisk A/S, NVIDIA Corporation, Sanofi SA, Tempus Labs, Inc., and Wipro Limited.
Market Segmentation & Coverage